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Background: Oxidized LDL (oxLDL) is involved in the development of atherosclerotic heart disease through a
mechanism that is not fully understood. In this study, we examined the role of malondialdehyde (MDA), an
important oxidative stress epitope of oxLDL, in mediating coronary endothelial cytotoxicity.
Results: Human coronary artery endothelial cells (HCAECs) were treated with oxLDL in the presence or absence of
antibody against MDA (anti-MDA) or apoB100 (anti-apoB100). In HCAECs treated with oxLDL (100 μg/ml) alone,
DNA synthesis, cell viability, and expression of prosurvival fibroblast growth factor 2 (FGF2) were significantly
reduced (P < 0.01 vs phosphate buffered saline–treated cells). These inhibitory effects of oxLDL were significantly
attenuated in HCAECs cotreated with anti-MDA (0.15 μg/ml; P < 0.05 vs oxLDL-treated cells), but not in those
cotreated with anti-apoB100. When we tested the effects of a panel of signal transduction modifiers on the signal
transduction pathways of MDA in oxLDL-treated HCAECs, we found that MDA-induced cytotoxicity was mediated
partly through the Akt pathway. Using a reporter gene assay, we identified an oxLDL-response element in the FGF2
promoter that was responsible for the transcriptional repression of FGF2 by oxLDL. The results of bisulfite genomic
DNA sequencing showed that in HCAECs treated with oxLDL, the GC-rich promoter of FGF2 was heavily methylated
at cytosine residues, whereas cotreatment with anti-MDA markedly reduced oxLDL-induced FGF2 promoter
methylation.
Conclusion: OxLDL disrupts the growth and survival of HCAECs through an MDA-dependent pathway involving
methylation of the FGF2 promoter and repression of FGF2 transcription. This novel epigenetic mechanism of
oxLDL may underlie its atherogenicity in patients with atherosclerotic cardiovascular disease.
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Oxidized low-density lipoprotein (oxLDL) has been shown
to accumulate in atherosclerotic lesions, and a growing
body of evidence indicates that oxLDL is involved in the
pathogenesis of coronary artery disease, acute coronary
syndrome, and vulnerable plaque [1]. Experimentally,
oxLDL exposure induces a variety of effects in endothelial
cells (ECs), such as the release of chemokines, cytokines,
and growth factors; the expression of surface molecules* Correspondence: pychang@ntu.edu.tw
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reproduction in any medium, provided the orthat regulate endothelial permeability and hemostatic
properties; and changes in cell growth, division, and death
[2,3]. The pathophysiologic effects of oxLDL observed
in vitro have been implicated in the initiation and progres-
sion of atherosclerosis in vivo [4].
Malondialdehyde (MDA) is an end-product of the
radical-initiated oxidative decomposition of polyunsatur-
ated fatty acids; therefore, it is frequently used as a bio-
marker of oxidative stress [5]. Clinical data have indicated
that MDA-type epitopes are prominent and prevalent and
are important in cardiovascular disease; thus, these anti-
gens are key candidates for use in characterizing immune
responses that are relevant to atherosclerosis [6,7]. The
Veterans Affairs Diabetes Trial, a recent clinical trial thatd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mellitus, showed that the levels of MDA-LDL in circulat-
ing immune complexes can predict the occurrence of
myocardial infarction and acute cardiovascular events in
patients with type 2 diabetes [8]. However, the precise
mechanism by which MDA might be causing endothelial
cytotoxicity is not known.
OxLDL has suppressive effects on genes that regulate
endothelial function, such as nitric oxide synthase [9].
Furthermore, oxLDL can modulate the signal transduc-
tion pathway of receptor Gi coupling by downregulating
the expression of heterotrimeric G protein Gαi2 [10]. In
addition, we have previously shown that the endothelial
damage caused by oxLDL is accompanied by the selective
downregulation of fibroblast growth factor 2 (FGF2) and
can be prevented by supplementing cells with exogenous
FGF2 [11,12]. Using an in vitro model of angiogenesis,
we also showed that capillary-like microtube growth
was impaired in arterial explants from hypercholester-
olemic rabbits or in those from normocholesterolemic
rabbits exposed to oxLDL in vitro and that this re-
duced microtube growth was associated with reduced
FGF2 concentrations in the culture medium of the ex-
plants [13]. The downregulation of FGF2 expression, there-
fore, has become a recognized mechanism of endothelial
dysfunction.
FGF2 is a pleiotropic protein that regulates a wide
range of functions and has angiogenic and anti-apoptotic
effects on vascular ECs [14,15]. The reduction of FGF2
levels in ECs has detrimental effects, such as massive
apoptosis and greatly impaired angiogenic responses [13].
When ECs are treated with homocysteine, FGF2 is down-
regulated at the transcriptional level by a mechanism
involving DNA methylation of the GC-rich FGF2 pro-
moter [16]. However, how oxLDL and its oxidative
stress epitopes, such as MDA, regulate transcription of
FGF2 is not known. In this study, we examined the
role of MDA in mediating coronary endothelial cyto-
toxicity and addressed the question of whether oxLDL
downregulates endothelial FGF2 via a signaling pathway
that involves DNA methylation. We have identified a
mechanistic model of EC gene modulation influenced by
oxLDL and MDA epitopes.
Methods
Cells and preparation of LDL
Human coronary artery ECs (HCAECs, Clonetics, USA)
were maintained from passages 4 to 7 in microvascular
endothelial cell growth medium (EGM-MV) supple-
mented with 20% fetal bovine serum and antibiotics
(100 μg/ml streptomycin, 100 IU/ml penicillin, and
0.25 μg/ml amphotericin B). Oxidized LDL was prepared
as previously described [11,12], and precautions were
taken to prevent endotoxin contamination. The proteinconcentration of each LDL preparation was determined
by using the Lowry method, and thiobarbituric acid–
reactive substances (TBARS) were determined as a
measure of oxidative lipid modification [11,12].
DNA synthesis analysis, cell counting, and enzyme-linked
immunosorbent assay (ELISA)
For the DNA synthesis and intracellular FGF2 protein as-
says, HCAECs (1 × 106) were seeded in each well of 12-
well Corning cell culture plates (Corning, USA). HCAECs
were incubated for 24 hours with or without oxLDL
(100 μg/ml) in the presence of phosphate-buffered saline
(PBS), goat polyclonal anti-MDA (0.01, 0.05, 0.10, or
0.15 mg/ml), anti-apoB100 (0.15 μg/ml) (both antibodies
from Academy Bio-Medical Co., USA) [17], preimmune
goat serum, or recombinant soluble human FGF2 (50 ng/ml;
Upstate Biotechnology, USA). DNA synthesis was quantified
by measuring 3H-thymidine incorporation, as previously
described [11,12]. 3H-thymidine was from Moravek
Biochemicals, Inc. (USA) or DuPont NEN (USA). Cells
were viewed under an inverted microscope and were
counted by using a hemocytometer. The percentage of
dead cells was determined according to trypan blue posi-
tivity. FGF2 concentrations were measured with an ELISA
by using a Quantikine kit (R&D Systems, USA), as previ-
ously described [11].
Reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed with total RNA and PCR primers
for FGF2 or the gene encoding β-actin (used as an internal
control), according to a previously described protocol
[12]. The FGF2 primers were as follows: 5′-GGA-GTG-
TGT-GCT-AAC-CGT-TAC-CTG-GCT-ATG-3′ (upstream)
and 5′-TCA-GCT-CTT-AGC-AGA-CAT-TGG-AAG-
AAA-AAG-3′ (downstream). β-actin primers were as
follows: 5′-AAC-CGC-GAG-AAG-ATG-ACC-CAG-ATC-
ATG-TTT-3′ (upstream) and 5′-AGC-AGC-CGT-GGC-
CAT-CTC-TTG-CTC-GAA-GTC-3′ (downstream). A
fraction of each PCR product (10 μl) was analyzed by
using gel electrophoresis (2% agarose), and DNA bands
were stained with ethidium bromide and visualized by
using ultraviolet transillumination. Densitometric quantifi-
cation was performed by using a PhosphorImager
(Molecular Dynamics, USA).
Inhibitors of signal transduction pathways
To characterize the involvement of major signal trans-
duction pathways, cells treated with or without anti-
MDA were also treated with 100 ng/ml pertussis toxin
(PTX, a Gi protein inhibitor), 1 μg/ml Akt inhibitor
(1 L6-hydroxymethyl-chiro-inositol-2-[R]-2-O-methyl-3-
O-octadecyl-sn-glycerocarbonate), or 0.4 μg/ml 5-aza-
deoxycytidine (5-aza-dC; a methylation inhibitor) for
24 hours before exposure to oxLDL (100 μg/ml). All agents
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dividual agents were determined on the basis of the max-
imal doses and durations tolerable by the cells;
tolerability was defined as <10% reduction in cell via-
bility, as determined by using the MTT assay.
Cell viability MTT assay
HCAECs (5 × 104 cells/well) were dispensed into 24-well
plates and incubated for 24 hours with oxLDL (100 μg/ml)
in the presence or absence of different treatments, and the
index of EC viability was determined by using the colori-
metric tetrazolium (MTT) assay. Absorbance was mea-
sured at a wavelength of 540 nm for viable cells by using a
microplate reader (Thermo Electron Corporation, USA).
DNA constructs, cell transfection, and luciferase reporter
gene assay
The reporter gene assay was performed by using a dual-
luciferase expression system (Promega, USA). Human
FGF2 5′-flanking sequences [18] were amplified from
human genomic DNA by using PCR, cloned into the
pGL3-basic firefly luciferase reporter vector (Promega,
USA), and sequenced. HCAECs were grown to 80% con-
fluency in plastic 12-well plates and then transfected
with 0.75 μg of pGL3-basic or an equimolar amount of
the different pGL3-FGF2 constructs by using Superfect™
reagent, according to the manufacturer’s instructions
(Qiagen, USA). Cotransfection with 0.5 μg of the Renilla
luciferase expression vector phRL-TK was used as an in-
ternal control. Twenty-four hours after transfection, the
cells were treated for 24 hours with 100 μg/ml oxLDL.
Cell lysates were then prepared for luciferase assays by
using Luciferin and a luminometer (Packard Instrument
Company, Inc., USA). The promoter activity of the re-
porter construct was normalized to the promoter activity
of phRL-TK and expressed as the fold increase relative
to that in cells transfected with pGL3-basic.
DNA sequence analysis and bisulfite genomic DNA
sequencing
The 5′-flanking sequence of the human FGF2 gene was
retrieved from GenBank and analyzed for CpG islands
by using “CpG Island Searcher,” available at the website
http://www.cpgislands.com [19,20]. Transcription factor
binding sites were analyzed by using the TRANSFAC
database, available at http://www.gene-regulation.com/.
To study DNA methylation, HCAECs that were cultured
to 80% to 90% confluency were subjected to different
treatments, followed by genomic DNA extraction per-
formed according to standard procedures. With the use
of the EpiTect bisulfite kit (Qiagen, USA), the reaction
of genomic DNA (2 μg) with bisulfite converted all
unmethylated cytosine residues to uracil. Bisulfite-modifiedDNA was amplified with FGF2-specific primers by using
previously described cycling conditions [16].
Statistical analysis
The significance of the differences between group means
was assessed by using a 2-way Student t test for single
comparisons and the Bonferroni test for multiple com-
parisons. Analysis of variance (ANOVA), followed by
Scheffé’s test for significance was used to compare values
for concentration- and time-dependent responses. Prob-
ability values <0.05 were considered significant. Results
are expressed as the mean ± SEM.
Results
MDA mediates the effects of oxLDL on DNA synthesis, EC
survival, and FGF2 expression
The exposure of HCAECs to oxLDL for 24 hours decreased
DNA synthesis and cell viability in a concentration-
dependent manner (Additional file 1: Figure S1). At a
concentration of 100 μg/ml, oxLDL significantly re-
duced DNA synthesis and cell viability (P < 0.05 vs un-
treated control cells) without significantly increasing
the percentage of dead cells (Additional file 1: Figure S1).
At concentrations >100 μg/ml, oxLDL not only signifi-
cantly decreased DNA synthesis and cell viability, but it
also significantly increased the percentage of dead cells
(P < 0.01; Additional file 1: Figure S1). Therefore, we
used an oxLDL concentration of 100 μg/ml for all sub-
sequent experiments.
After HCAECs were treated with oxLDL (100 μg/ml)
for 24 hours, DNA synthesis was decreased by 40% to
50% (Figure 1), a finding similar to those reported
previously [11,12]. Treatment of HCAECs with FGF2
(50 ng/ml) alone had a potent mitogenic effect (P < 0.05),
and cotreatment with FGF2 and oxLDL prevented the
oxLDL-mediated inhibition of DNA synthesis. The inhibi-
tory effect of oxLDL on DNA synthesis was also markedly
attenuated in HCAECs cotreated with 0.15 μg/ml anti-
MDA, but not in those cotreated with anti-apoB100
(Figure 1). Treatment of HCAECs with oxLDL alone
reduced the number of cells (Figure 2A) and signifi-
cantly increased the percentage of trypan blue–positive
cells (Figure 2B, P < 0.01 vs control), whereas treatment
with anti-MDA alone (0.15 μg/ml) had a negligible effect.
Cotreatment of HCAECs with anti-MDA and oxLDL at-
tenuated the cytotoxic effects of oxLDL (Figure 2A and B,
P < 0.05 vs oxLDL alone), whereas treatment with preim-
mune serum or anti-apoB100 had no protective effect
(Figure 2A and B).
Because anti-MDA prevented the antiproliferative ef-
fect of oxLDL, we examined the effects of anti-MDA on
FGF2 production by using ELISA. In HCAECs treated
with oxLDL (100 μg/ml), the intracellular FGF2 concen-
tration was decreased by 40% to 50% (Figure 3A, P < 0.05).
Figure 1 Role of the MDA epitope on the oxLDL-induced reduction of DNA synthesis, as determined by measuring 3H-thymidine
incorporation. Cultured human coronary artery endothelial cells were incubated for 24 hours with or without oxLDL (100 μg/ml) in the
presence or absence of anti-MDA (0.01, 0.05, or 0.15 μg/ml), anti-apoB100 (0.15 μg/ml), or FGF2 (50 ng/ml). Values shown are the mean ± SEM
(n = 3). *P< 0.05, **P< 0.01 vs the oxLDL-untreated, PBS-treated control (first black column). †P< 0.05 between the indicated pair. MDA, malondialdehyde;
oxLDL, oxidized low-density lipoprotein.
Figure 2 Role of the MDA epitope in oxLDL-induced human coronary artery endothelial cell (HCAEC) cytotoxicity. (A) HCAECs were
incubated for 24 hours with or without oxLDL (100 μg/ml) in the presence or absence of anti-MDA (0.15 μg/ml), preimmune serum, or anti-apoB100
(0.15 μg/ml), as indicated; control cells were treated with PBS. Cells are shown under the view of an inverted microscope. (B) Percentage of trypan blue–positive
cells expressed as the mean ± SEM (n = 3). **P<0.01 vs control. †P< 0.05 vs oxLDL alone. MDA, malondialdehyde; oxLDL, oxidized low-density lipoprotein.
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Figure 3 Effect of anti-MDA on oxLDL-regulated FGF2 expression. (A) Intracellular FGF2 protein concentrations in cultured human coronary
artery endothelial cells (HCAECs) are shown, as determined with ELISA. Cells were incubated for 24 hours with or without oxLDL (100 μg/ml) in
the presence or absence of anti-MDA (0.01, 0.05, 0.1, or 0.15 μg/ml). Values shown are the mean ± SEM (n = 3). *P < 0.05, **P < 0.01 vs the
oxLDL-untreated PBS control. †P < 0.05 vs the oxLDL-treated PBS control. (B) FGF2 mRNA levels in HCAECs relative to those in the PBS-treated
control, as determined by using RT-PCR. HCAECs were incubated for 24 hours with the indicated reagents, and total RNA was subjected to RT-PCR
analysis by using specific primers for FGF2 and the gene encoding β-actin (internal control). The upper panel shows a gel representative of 3
separate experiments, and the lower panel shows the densitometric quantification. MDA, malondialdehyde; oxLDL, oxidized low-density lipoprotein.
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between cells treated with PBS and those treated with
anti-MDA (0.01-0.15 μg/ml); however, in oxLDL-treated
cells, cotreatment with anti-MDA attenuated the inhibi-
tory effect of oxLDL on FGF2 expression in a dose-dependent manner (Figure 3A, P < 0.05 vs PBS + oxLDL).
In addition, RT-PCR analysis showed that oxLDL reduced
FGF2 mRNA levels by ~50% when compared to the PBS
control—an effect that was prevented by anti-MDA (0.15
μg/ml) but not anti-apoB100 (0.15 μg/ml) (Figure 3B).
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involve DNA methylation
To investigate the signal transduction pathways of MDA
in oxLDL-treated HCAECs, we examined the effects of
pharmacologic inhibitors on cell viability (Figure 4).
Compared with cells treated with PBS only (first black
column), cells also treated with oxLDL (100 μg/ml) for
24 hours showed a 40% decrease in cell viability. This in-
hibitory effect of oxLDL was remarkably blocked in cells
cotreated with either PTX, a G protein inhibitor, or with
5-aza-dC, a methylation inhibitor. When HCAECs were
cotreated with both oxLDL and anti-MDA, the oxLDL-
induced reduction in cell viability was blocked, which
was unaffected by the addition of PTX or 5-aza-dC.
However, the addition of Akt inhibitor significantly
attenuated the effect of anti-MDA (last column). These re-
sults indicate that the Akt signaling pathway and DNA
methylation are involved in mediating cell proliferation
in anti-MDA/oxLDL-treated HCAECs.
The FGF2 promoter is regulated by oxLDL and MDA
To determine whether the reduced FGF2 expression ob-
served in oxLDL-treated cells resulted from decreased
FGF2 gene transcription, we evaluated FGF2 promoter ac-
tivity in the presence or absence of oxLDL (100 μg/ml) byFigure 4 Effects of signal transduction inhibitors on the oxLDL-induce
assay in cultured human coronary artery endothelial cells (HCAECs). H
the presence or absence of oxLDL (100 μg/ml) and anti-MDA (0.15 μg/ml), as
of the PBS control (first black column). Values shown are mean ± SEM (n = 3).
pair. 5-aza-dC, 5-aza-deoxycytidine; Akt inh, Akt inhibitor; MDA, malondialdehyusing a luciferase reporter gene assay. Human FGF2 gen-
omic sequences containing the FGF2 promoter were gen-
erated by using PCR and were cloned into the firefly
luciferase vector, pGL3 (Figure 5A). In the absence of
oxLDL, the –126/+ 43 and –126/+179 constructs contain-
ing the FGF2 promoter induced FGF2 gene expression
120-fold more than did the pGL3-basic vector (Figure 5B).
Deletion of the FGF2 promoter from position –126 to + 24
resulted in an 80% reduction in FGF2 gene expression,
confirming the removal of a basal promoter in this region.
The addition of oxLDL (100 μg/ml) reduced FGF2 expres-
sion in cells transfected with constructs –126/+ 43 and –
126/+179 by 30% to 40% (P < 0.05). However, the presence
of anti-MDA prevented the oxLDL-induced repression of
FGF2 promoter activity. Furthermore, attenuation of the
oxLDL-induced repression of FGF2 promoter activity
by anti-MDA was partially prevented by Akt inhibitor
(Additional file 1: Figure S2), suggesting the involve-
ment of Akt in the regulation of FGF2 expression by
MDA and oxLDL. Our results suggest that FGF2
transcription in HCAECs can be repressed by oxLDL
and that this effect is mediated through the MDA
epitope. The preservation of FGF2 promoter activity
by anti-MDA is in agreement with our RT-PCR re-
sults (Figure 3B).d reduction of cell viability, as determined by using the MTT
CAECs were incubated for 24 hours with signaling pathway modifiers in
indicated. The cell viability after each treatment was normalized to that
*P < 0.05 vs control (first black column); **P < 0.05 between the indicated
de; oxLDL, oxidized low-density lipoprotein; PTX, pertussis toxin.
Figure 5 Effects of anti-MDA and oxLDL on the transcriptional regulation of FGF2 in cultured human coronary artery endothelial cells
(HCAECs). (A) A diagram showing the different FGF2 reporter gene constructs used. Different lengths of human FGF2 5′-flanking sequences were
cloned into the pGL3-basic luciferase reporter vector. +1 indicates the transcription start site. (B) FGF2 promoter activity is shown, as determined
by using a luciferase reporter gene assay. HCAECs were cotransfected with the indicated constructs and phRL-TK (internal control) and were
incubated for 24 h with or without oxLDL (100 μg/ml) in the presence or absence of anti-MDA (0.15 μg/ml). Luciferase activities are
expressed relative to those in cells transfected with pGL3-basic. Values shown are the mean ± SEM (n = 3-5). *P < 0.05 vs corresponding
oxLDL-untreated controls. Luc, luciferase reporter gene; MDA, malondialdehyde; oxLDL, oxidized low-density lipoprotein.
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methylation of a CpG island
Genomic sequence analysis of human FGF2 confirmed
the absence of a TATA sequence and revealed the pres-
ence of multiple GC boxes (GGGCGG or CCGCCC)
(Figure 6). Using the “CpG Island Searcher” database to
search for CpG dinucleotides, we identified a 1877-bp
CpG island that starts at –532 in the 5′-flanking region
of FGF2 and extends through exon 1 into the first in-
tron. This portion of the human FGF2 gene contains the
oxLDL-responsive promoter that we previously showed
can be regulated by homocysteine [16]. A computer scan
of the TRANSFAC database disclosed several possible
binding sites for transcription factors, including 2 GC
boxes in the oxLDL/MDA-responsive promoter (Figure 6).
Because CpG methylation is a key factor for FGF2
gene expression, we investigated whether MDA mediatesthe oxLDL-induced suppression of FGF2 expression through
this epigenetic modification. The methylation status of CpG
dinucleotides in the FGF2 promoter was characterized by
performing bisulfite genomic DNA sequencing in HCAECs
(Figure 7). Twenty CpG dinucleotides (numbered 1–20 in
Figure 7) in the FGF2 promoter region were analyzed by
using 2 pairs of primers (CpG primer 1S/1AS; CpG primer
2S/2AS) designed to amplify the FGF2 promoter region
(Figure 7A). In PBS-treated control cells, none of the
20 cytosine residues was methylated (Figure 7B). In
contrast, all 20 cytosine residues were methylated in
cells treated with oxLDL (100 μg/ml). Furthermore,
when anti-MDA was added to oxLDL-treated HCAECs,
methylation of the cytosine residues was markedly re-
duced: only 4 of the 20 remained methylated (Figure 7B).
To determine whether oxLDL induced the upregulation
of DNA methyltransferases in HCAECs, we examined the
Figure 6 The human FGF2 gene promoter. (A) Schematic representation of the CpG island promoter of human FGF2. The numbers are the
nucleotide positions relative to the +1 transcription start site. Each CpG dinucleotide is shown by a vertical line. (B) Part of the genomic DNA
sequence of FGF2 is shown, featuring the FGF2 promoter, GC boxes (outlined), and CpG dinucleotides (shaded). The CpG island start site
(downward arrow in B), the exon-intron boundary (triangle in B), and the translation start codon (CTG in B) are indicated.
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DNMT3A, and DNMT3B by using real-time PCR. We
observed a modest oxLDL-induced increase in the
levels of DNMT1 and DNMT3B mRNA, which was at-
tenuated by anti-MDA (Additional file 1: Figure S3).
These data indicate that oxLDL represses FGF2 tran-
scription in ECs by promoting the methylation of CpG
dinucleotides in the FGF2 promoter—an action that is
mediated through the oxidative MDA epitope of oxLDL.
Discussion
The aim of this study was to elucidate the mechanisms
underlying the regulation of cell proliferation and FGF2
expression in ECs exposed to oxLDL. We found that
oxLDL-induced EC damage can be prevented by anti-
MDA, which blocks the oxLDL-induced reduction of
intracellular FGF2 levels through an Akt-dependent
pathway. Furthermore, the effect of MDA was mediatedthrough the transcriptional repression of the FGF2
promoter, which involved CpG methylation. Thus, we
showed that MDA exerts its deleterious effects on ECs
through an FGF2-dependent pathway, which may be
the mechanism underlying the atherogenic nature of
oxLDL. The schematic in Figure 8 outlines the signal-
ing pathway through which MDA mediates endothelial
cytotoxicity in the presence of oxLDL.
FGF2, a potent angiogenic factor involved in all as-
pects of angiogenesis (eg, EC proliferation and migration
and vascular differentiation), is an indicator of EC sur-
vival [21,22]. Previously, we showed that both oxLDL
and electronegative LDL downregulate endothelial FGF2
expression by inhibiting Gi, a heterotrimeric G protein
[11,12]. In the current study, PTX, a Gi inhibitor, attenu-
ated oxLDL-mediated effects on FGF2 expression, fur-
ther supporting the important role of Gi protein in the
oxLDL signaling pathway. Because circulating oxLDL
Figure 7 FGF2 promoter analysis. (A) The CpG island sequence in the promoter region of human FGF2 is shown. The human FGF2 promoter
contains 20 CpG sites, numbered 1-20. The primers used for DNA methylation sequencing are shown. (B) An illustration showing the methylation
status of the CpG dinucleotides in human coronary artery endothelial cells treated for 24 hours with oxLDL (100 μg/ml) in the presence or
absence of anti-MDA (0.15 μg/ml). Unmethylated cytosines are indicated by stalks. Methylated cytosines are indicated by stalks with
square heads. MDA, malondialdehyde; oxLDL, oxidized low-density lipoprotein.
Figure 8 A schematic illustration of FGF2 regulation by the MDA epitope of oxLDL in human coronary artery endothelial cells. The
transcription start site of the FGF2 gene is indicated as +1. Methylation of the cytosine residues of CpG dinucleotides is indicated by –CH3. Arrows
indicate stimulation or direction of transportation. Lines with an end bar indicate inhibition.
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who have coronary events [5-8,23], FGF2 downregulation
by oxLDL may be an important mechanism underlying
the impaired angiogenic response in atherosclerosis. In
addition, involvement of the MDA epitope in oxLDL-
induced angiostatic effects supports the use of MDA as a
biomarker in cardiovascular diseases [5-8].
Although oxLDL is known to modulate the expression
of many genes, its effect on FGF2 promoter activity has
not been previously reported. We found that the oxLDL-
induced downregulation of FGF2 expression is caused by
transcriptional repression of the FGF2 gene promoter and
that this repression could be effectively prevented by
5-aza-dC. The 5′-flanking regions of the FGF2 pro-
moter are responsible for the basal transcription of
the FGF2 gene, the subcellular distribution of FGF2
protein in adrenal medullary cells [18,24], and the cell
density–dependent regulation of FGF2 levels in human as-
trocytes [25]. In the current study, we identified a 5′-flanking
region in the FGF2 promoter from –126 to +24 (which
conforms to the published mapping of the FGF2 gene
promoter) that functions as an oxLDL-responsive
element. The FGF2 promoter is located in a CpG is-
land, which is defined as a region of DNA larger than
500 bp that has a moving average %(G + C) greater
than 55 and an observed/expected CpG dinucleotide
ratio greater than 0.65 [19,20]. The CpG island of the
human FGF2 gene contains multiple GC boxes (GGGCGG
or CCGCCC) and a basal promoter, which responded to
oxLDL in our transient transfection system. We found that
the CpG-rich FGF2 promoter was heavily methylated by
oxLDL, resulting in the subsequent suppression of FGF2
transcription.
Previously, we have shown that L5, the most electro-
negative subfraction of LDL obtained by using anion-
exchange chromatography, downregulates endothelial
FGF2 expression at the transcriptional level by inhibiting
Akt phosphorylation [26]. Furthermore, it has been
shown that the L5-induced reduction in FGF2 expres-
sion can be attenuated by aspirin through a signaling
pathway that requires Akt [27]. In the present study, the
ability of Akt inhibitor to counteract the effects of anti-
MDA in HCAECs further supports the important role of
Akt in the oxLDL-FGF2 signaling pathway. Moreover,
the involvement of Akt in the regulation of the FGF2
promoter by oxLDL also implies a complex interplay be-
tween cellular survival and different signaling pathways
in the response to atherogenic oxLDL.
Epigenetics is a phenomenon characterized by herit-
able changes in the phenotypic expression of genetic in-
formation that occurs without changes in DNA sequence.
Emerging data suggest that epigenetic modifications affect
the development of cardiovascular diseases, such as hu-
man heart failure and atherosclerosis [28,29]. DNAmethylation, an epigenetic modification that occurs
throughout the genome, is the addition of a methyl
group to the cytosine residues preceding a guanosine
(ie, CpG dinucleotides). This modification has been
studied extensively and represents a well-understood
epigenetic mechanism. Abnormal methylation of CpG
islands in the promoter region of genes can be caused
by exogenous stimuli such as smoking and oxidative
stress, often leading to the silencing of genetic information
and subsequent alterations in biologic function [30].
OxLDL has been shown to alter DNA promoter
methylation in cultured ECs. In human umbilical vein
ECs (HUVECs), oxLDL-induced apoptosis has been as-
sociated with upregulation of the proapoptotic genes
LOX-1, ANXA5, BAX, and CASP3 and inhibition of the
anti-apoptotic genes BCL2 and cIAP-1. Interestingly, the
upregulation of these apoptosis-related genes was con-
sistently accompanied by reciprocal changes in the
methylation of the respective promoter regions [31].
However, promoter methylation induced by oxLDL is
not always accompanied by reciprocal changes in gene
expression. At different concentrations, oxLDL can dif-
ferentially regulate the methylation status of the estro-
gen receptor alpha gene [32]. In addition, oxLDL can
upregulate microRNA-29b, leading to epigenetic modi-
fications of the matrix metalloproteinase (MMP)-2/
MMP-9 genes [33]. Our discovery that the oxLDL-
induced downregulation of FGF2 expression can be at-
tenuated by 5-aza-dC, a well-known demethylating reagent
[34], also supports that oxLDL promotes hypermethylation
of the FGF2 promoter, as illustrated in Figure 8.
Our study shows that oxLDL can specifically downreg-
ulate FGF2 expression in arterial ECs, revealing a novel,
angiostatic function for oxLDL. Because oxLDL and
homocysteine are both risk factors for atherosclerosis,
the possibility remains that they synergistically promote
EC cytotoxicity through a shared pathway related to
FGF2 [16]. The notion that there is close interplay be-
tween homocysteine and oxLDL has been suggested by
previous findings showing that homocysteine enhances
the oxidation of human LDL in HUVECs and facilitates
the subsequent uptake of oxLDL by macrophages [35].
Moreover, homocysteine can upregulate the expression of
lectin-like oxLDL receptor-1 (LOX-1) in endothelial and
mononuclear cells and increase the toxicity of oxLDL
[36]. Collectively, our results support the idea that cross-
talk occurs between the cardiovascular risk factors oxLDL
and homocysteine and that the upregulation or reintro-
duction of FGF2 may counteract their pathologic effects
in ECs.
Conclusions
We have shown that oxLDL-induced impairment of EC
integrity and survival is mediated by the MDA epitope
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regulation of intracellular FGF2. This signaling pathway
through which MDA mediates endothelial cytotoxicity
in the presence of oxLDL is outlined in Figure 8. Be-
cause high circulating levels of oxLDL and MDA-LDL
are strongly associated with atherosclerotic diseases
[37,38], we propose that the maintenance of FGF2 ex-
pression may provide protection of the endothelium in
patients with these diseases. Furthermore, DNA de-
methylation may have therapeutic applications for pro-
tecting ECs against oxLDL-induced cell death and for
preventing plaque instability.
Additional files
Additional file 1: Figure S1. Effects of oxLDL on DNA synthesis, cell
viability, and cell death in cultured HCAECs. Cells were treated with
increasing concentrations of oxLDL for 24 hours, and DNA synthesis (•),
cell viability (□), and cell death (Δ) were assessed. Values are expressed as
the mean±SEM (n=3). *P < 0.05, **P < 0.01 vs corresponding untreated
controls. Figure S2. Involvement of DNA methylation and Akt signaling
pathway in FGF2 promoter regulation. Human coronary artery endothelial
cells (HCAECs) were cotransfected with the reporter constructs -126/+179
or -126/+179 and phRL-TK (internal control), followed by incubation with
L5 (100 μg/ml), 5-aza-dC (5-aza-deoxycytidine, 0.4 μg/ml), or Akt inhibitor
(1 μg/ml) in the presence or absence of anti-MDA (0.15 μg/ml). Luciferase
activity was expressed as a fold-increase of that for pGL3-basic. Values are
expressed as the mean±SEM and are representative of 3 to 5 independent
experiments. *P < 0.05 between the indicated pair. PBS, phosphate-buffered
saline. Figure S3. Effects of oxLDL on DNA methyltransferase (DNMT) mRNA
expression. Human coronary artery endothelial cells (HCAECs) were incubated
with phosphate-buffered saline (PBS), native LDL (100 μg/ml), anti-MDA
(0.15 μg/ml), oxLDL (100 μg/ml), or oxLDL+anti-MDA as indicated for
24 hours, and total RNA was subjected to real-time polymerase chain
reaction analysis with specific primers for DNMT1, DNMT3A, DNMT3B,
and β-actin. The values in the graph are expressed relative to that of
the PBS control after normalization to β-actin and are presented as
the mean ± SEM representative of 3 to 5 independent experiments. *P < 0.05
vs PBS-treated control; **P < 0.05 between the indicated pair (oxLDL+anti-MDA
and oxLDL alone). Table S1. Primer sequences used for real-time polymerase
chain reaction (PCR), reporter gene constructs, and CpG methylation studies.
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